148 related articles for article (PubMed ID: 37028108)
1. miRNAs as potential game-changers in renal cell carcinoma: Future clinical and medicinal uses.
Elballal MS; Sallam AM; Elesawy AE; Shahin RK; Midan HM; Elrebehy MA; Elazazy O; El-Boghdady RM; Blasy SH; Amer NM; Farid HI; Mohammed DA; Ahmed SA; Mohamed SS; Doghish AS
Pathol Res Pract; 2023 May; 245():154439. PubMed ID: 37028108
[TBL] [Abstract][Full Text] [Related]
2. MicroRNAs Associated with Von Hippel-Lindau Pathway in Renal Cell Carcinoma: A Comprehensive Review.
Schanza LM; Seles M; Stotz M; Fosselteder J; Hutterer GC; Pichler M; Stiegelbauer V
Int J Mol Sci; 2017 Nov; 18(11):. PubMed ID: 29165391
[TBL] [Abstract][Full Text] [Related]
3. miR-566 functions as an oncogene and a potential biomarker for prognosis in renal cell carcinoma.
Pan X; Quan J; Li Z; Zhao L; Zhou L; Jinling X; Weijie X; Guan X; Li H; Yang S; Gui Y; Lai Y
Biomed Pharmacother; 2018 Jun; 102():718-727. PubMed ID: 29604591
[TBL] [Abstract][Full Text] [Related]
4. miR-145 functions as tumor suppressor and targets two oncogenes, ANGPT2 and NEDD9, in renal cell carcinoma.
Lu R; Ji Z; Li X; Zhai Q; Zhao C; Jiang Z; Zhang S; Nie L; Yu Z
J Cancer Res Clin Oncol; 2014 Mar; 140(3):387-97. PubMed ID: 24384875
[TBL] [Abstract][Full Text] [Related]
5. Sunitinib-suppressed miR-452-5p facilitates renal cancer cell invasion and metastasis through modulating SMAD4/SMAD7 signals.
Zhai W; Li S; Zhang J; Chen Y; Ma J; Kong W; Gong D; Zheng J; Xue W; Xu Y
Mol Cancer; 2018 Nov; 17(1):157. PubMed ID: 30419914
[TBL] [Abstract][Full Text] [Related]
6. MicroRNAs in Renal Cell Carcinoma.
Sellitti DF; Doi SQ
Microrna; 2015; 4(1):26-35. PubMed ID: 26165467
[TBL] [Abstract][Full Text] [Related]
7. The biological roles and clinical implications of microRNAs in clear cell renal cell carcinoma.
He YH; Chen C; Shi Z
J Cell Physiol; 2018 Jun; 233(6):4458-4465. PubMed ID: 29215721
[TBL] [Abstract][Full Text] [Related]
8. Dysregulation of kallikrein-related peptidases in renal cell carcinoma: potential targets of miRNAs.
White NM; Bui A; Mejia-Guerrero S; Chao J; Soosaipillai A; Youssef Y; Mankaruos M; Honey RJ; Stewart R; Pace KT; Sugar L; Diamandis EP; Doré J; Yousef GM
Biol Chem; 2010 Apr; 391(4):411-23. PubMed ID: 20180642
[TBL] [Abstract][Full Text] [Related]
9. microRNA‑572 functions as an oncogene and a potential biomarker for renal cell carcinoma prognosis.
Pan X; Li Z; Zhao L; Quan J; Zhou L; Xu J; Xu W; Guan X; Li H; Yang S; Gui Y; Lai Y
Oncol Rep; 2018 Nov; 40(5):3092-3101. PubMed ID: 30132566
[TBL] [Abstract][Full Text] [Related]
10. Clinical utility of microRNAs in renal cell carcinoma: current evidence and future perspectives.
Tsiakanikas P; Giaginis C; Kontos CK; Scorilas A
Expert Rev Mol Diagn; 2018 Nov; 18(11):981-991. PubMed ID: 30345829
[TBL] [Abstract][Full Text] [Related]
11. Identification of mutations associated with acquired resistance to sunitinib in renal cell cancer.
Elgendy M; Fusco JP; Segura V; Lozano MD; Minucci S; Echeveste JI; Gurpide A; Andueza M; Melero I; Sanmamed MF; Ruiz MR; Calvo A; Pascual JI; Velis JM; Miñana B; Valle RD; Pio R; Agorreta J; Abengozar M; Colecchia M; Brich S; Renne SL; Guruceaga E; Patiño-García A; Perez-Gracia JL
Int J Cancer; 2019 Oct; 145(7):1991-2001. PubMed ID: 30848481
[TBL] [Abstract][Full Text] [Related]
12. Tumor suppressive microRNA‑138 contributes to cell migration and invasion through its targeting of vimentin in renal cell carcinoma.
Yamasaki T; Seki N; Yamada Y; Yoshino H; Hidaka H; Chiyomaru T; Nohata N; Kinoshita T; Nakagawa M; Enokida H
Int J Oncol; 2012 Sep; 41(3):805-17. PubMed ID: 22766839
[TBL] [Abstract][Full Text] [Related]
13. MiR-210 expression in tumor tissue and in vitro effects of its silencing in renal cell carcinoma.
Redova M; Poprach A; Besse A; Iliev R; Nekvindova J; Lakomy R; Radova L; Svoboda M; Dolezel J; Vyzula R; Slaby O
Tumour Biol; 2013 Feb; 34(1):481-91. PubMed ID: 23150176
[TBL] [Abstract][Full Text] [Related]
14. miRNAs as potential regulators of mTOR pathway in renal cell carcinoma.
Nogueira I; Dias F; Teixeira AL; Medeiros R
Pharmacogenomics; 2018 Feb; 19(3):249-261. PubMed ID: 29334302
[TBL] [Abstract][Full Text] [Related]
15. MicroRNAs in the pathogenesis of renal cell carcinoma and their diagnostic and prognostic utility as cancer biomarkers.
Fedorko M; Pacik D; Wasserbauer R; Juracek J; Varga G; Ghazal M; Nussir MI
Int J Biol Markers; 2016 Feb; 31(1):e26-37. PubMed ID: 26481440
[TBL] [Abstract][Full Text] [Related]
16. miRNA profiling in metastatic renal cell carcinoma reveals a tumour-suppressor effect for miR-215.
White NM; Khella HW; Grigull J; Adzovic S; Youssef YM; Honey RJ; Stewart R; Pace KT; Bjarnason GA; Jewett MA; Evans AJ; Gabril M; Yousef GM
Br J Cancer; 2011 Nov; 105(11):1741-9. PubMed ID: 22033272
[TBL] [Abstract][Full Text] [Related]
17. Circulating miR-378 and miR-451 in serum are potential biomarkers for renal cell carcinoma.
Redova M; Poprach A; Nekvindova J; Iliev R; Radova L; Lakomy R; Svoboda M; Vyzula R; Slaby O
J Transl Med; 2012 Mar; 10():55. PubMed ID: 22440013
[TBL] [Abstract][Full Text] [Related]
18. Identification of MicroRNAs associated with early relapse after nephrectomy in renal cell carcinoma patients.
Slaby O; Redova M; Poprach A; Nekvindova J; Iliev R; Radova L; Lakomy R; Svoboda M; Vyzula R
Genes Chromosomes Cancer; 2012 Jul; 51(7):707-16. PubMed ID: 22492545
[TBL] [Abstract][Full Text] [Related]
19. MicroRNA expression signatures of stage, grade, and progression in clear cell RCC.
Gowrishankar B; Ibragimova I; Zhou Y; Slifker MJ; Devarajan K; Al-Saleem T; Uzzo RG; Cairns P
Cancer Biol Ther; 2014 Mar; 15(3):329-41. PubMed ID: 24351440
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of c-FLIPL expression by miRNA-708 increases the sensitivity of renal cancer cells to anti-cancer drugs.
Kim EA; Kim SW; Nam J; Sung EG; Song IH; Kim JY; Kwon TK; Lee TJ
Oncotarget; 2016 May; 7(22):31832-46. PubMed ID: 27092874
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
